Gilead Sciences Files 8-K on Shareholder Votes and Exhibits

TL;DR

Gilead filed an 8-K on May 8th covering shareholder votes and financial exhibits.

AI Summary

Gilead Sciences, Inc. filed an 8-K on May 8, 2025, reporting on matters submitted to a vote of security holders and financial statements/exhibits as of May 7, 2025. The filing details their principal executive offices located at 333 Lakeside Drive, Foster City, California, 94404.

Why It Matters

This filing provides updates on corporate governance and financial reporting for Gilead Sciences, which is crucial for investors to understand the company's operational and shareholder-related activities.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of corporate actions and financial information, not indicating any immediate operational or financial distress.

Key Players & Entities

• GILEAD SCIENCES, INC. (company) — Registrant
• 333 Lakeside Drive, Foster City, California, 94404 (location) — Principal executive offices
• May 7, 2025 (date) — Date of earliest event reported
• May 8, 2025 (date) — Date of report

FAQ

From the Filing

0000882095-25-000015.txt : 20250508 0000882095-25-000015.hdr.sgml : 20250508 20250508172608 ACCESSION NUMBER: 0000882095-25-000015 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250507 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250508 DATE AS OF CHANGE: 20250508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19731 FILM NUMBER: 25927518 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 8-K 1 gild-20250507.htm FORM 8-K gild-20250507 0000882095 false 0000882095 2025-05-07 2025-05-07 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 7, 2025 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File No.) (IRS Employer Identification No.) 333 Lakeside Drive , Foster City , California (Address of principal executive offices) 94404 (Zip Code) 650 - 574-3000 (Registrant’s Telephone Number, Including Area Code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12 ☐      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ Item 5.07    Submission of Matters to a Vote of Security Holders. The 2025 annual meeting of stockholders (the “Annual Meeting”) of Gilead Sciences, Inc. (the “Company”) was held on May 7, 2025 . Of the 1,246,634,469 shares of the Company’s common stock entitled to vote at the Annual Meeting, 1,121,336,290 shares were represented at the beginning of the meeting in person or by proxy, which constituted a quorum. The voting results are presented below. The Company’s stockholders elected nine directors to serve for the next year and until their successors are elected and qualified. The votes regarding the election of directors we